Cargando…
Unanswered questions on the safety of MDT-U - Reply
Autores principales: | Penna, Gerson Oliveira, Gonçalves, Heitor de Sá, Pontes, Maria Araci de Andrade |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Dermatologia
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007019/ https://www.ncbi.nlm.nih.gov/pubmed/31644639 http://dx.doi.org/10.1590/abd1806-4841.201985641 |
Ejemplares similares
-
Unanswered questions on the safety of MDT-U
por: Barve, Ajit
Publicado: (2019) -
Clinical trial for uniform multidrug therapy for leprosy patients in
Brazil (U-MDT/CT-BR): adverse effects approach
por: Cruz, Rossilene Conceição da Silva, et al.
Publicado: (2018) -
Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR)
por: Hungria, Emerith Mayra, et al.
Publicado: (2017) -
Mycobacterium leprae-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT
por: Hungria, Emerith M., et al.
Publicado: (2018) -
Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients
por: Penna, Gerson Oliveira, et al.
Publicado: (2017)